New hope for bleeding disorder: experimental drug HMB-002 enters human trials
NCT ID NCT06754852
First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests a new medicine, HMB-002, for people with Von Willebrand disease (types 1 and 2), a bleeding disorder. The trial has two parts: first, a single dose to check safety and how the drug works in the body; second, repeated doses to see if it helps control bleeding. About 108 adults aged 18 to 64 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fiona Stanley Hospital
NOT_YET_RECRUITINGMurdoch, Perth, WA 6150, Australia
-
Richmond Pharmacology
RECRUITINGLondon, SE1 1YR, United Kingdom
-
Royal Prince Alfred Hospital
RECRUITINGCamperdown, Sydney, NSW 2050, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.